Organization
Verona Pharma
8 clinical trials
1 abstract
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Two-period Cross-over Study of the Effect of Ensifentrine on Sputum Markers of Inflammation in Patients With COPDStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19Status: Completed, Estimated PCD: 2021-02-15
Clinical trial
A Phase II, Randomized Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Dry Powdered Inhaler in Patients With COPDStatus: Completed, Estimated PCD: 2019-05-23
Clinical trial
A Phase II, Randomised Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Pressurised Metered Dose Inhaler in Patients With COPDStatus: Completed, Estimated PCD: 2020-12-10
Clinical trial
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPDStatus: Completed, Estimated PCD: 2022-09-12
Clinical trial
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseStatus: Completed, Estimated PCD: 2022-05-03
Clinical trial
A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.Status: Completed, Estimated PCD: 2017-11-03
Abstract
ASSOCIATION BETWEEN EXPOSURE TO FINE PARTICULATE MATTER AND OSTEOPOROSIS: A POPULATION-BASED COHORT STUDYOrg: University of Verona, Oncology Section, Rheumatology unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, Verona Pharma, Italy,
Clinical trial
A Study Assessing the Effect of Ensifentrine on CAT™ Scores Over 12 Weeks in Subjects With Moderate to Severe COPDStatus: Not yet recruiting, Estimated PCD: 2024-10-01